Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2026)

Denali Therapeutics (DNLI) has reported Total Current Liabilities for 10 consecutive years, with $110.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 19.9% year-over-year to $110.2 million; the TTM figure through Mar 2026 stood at $110.2 million (up 19.9% YoY), while the FY2025 annual figure was $98.4 million, down 3.77% from the prior year.
• Total Current Liabilities improved to $110.2 million in Q1 2026 per DNLI's latest filing, from $98.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $391.1 million in Q1 2023 and bottomed at $69.4 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $167.7 million across 5 years, with a median of $91.9 million in 2025.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 577.2% — and 2023, when it slumped 80.26%.
• Denali Therapeutics' Total Current Liabilities stood at $363.9 million in 2022, then tumbled by 78.57% to $78.0 million in 2023, then jumped by 31.07% to $102.2 million in 2024, then dropped by 3.77% to $98.4 million in 2025, then gained by 12.0% to $110.2 million in 2026.
• Business Quant data shows DNLI's Total Current Liabilities at $110.2 million in Q1 2026, $98.4 million in Q4 2025, and $90.1 million in Q3 2025.